ESPR EBITDA Growth
Esperion Therapeutics Inc · EBITDA Growth
ESPR EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported145.10%period ending
ESPR TTM EBITDA YoY % (-8.69% → 145.10%)
Year-over-year change
High-resolution chart · PNG
ESPR ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 145.0964% | |
| 697.7517% | |
| 3.7703% | |
| 19.2049% | |
| -223.2082% | |
| 105.3335% | |
| 81.0491% | |
| 75.5542% | |
| 84.8833% | |
| 14.8802% | |
| 19.7657% | |
| 18.3667% | |
| 0.5044% | |
| 20.6146% | |
| 29.7652% | |
| 30.6852% | |
| -41.066% | |
| -84.6053% | |
| -221.7515% | |
| -336.4899% | |
| 48.4229% | |
| -34.9399% | |
| 9.5712% | |
| 13.4615% | |
| -261.3498% | |
| 56.0837% | |
| 49.4613% | |
| 56.4429% | |
| 60.1921% | |
| -20.9498% | |
| -13.8352% | |
| -35.4389% | |
| -72.59% | |
| -125.8063% | |
| -170.7041% | |
| -141.3276% | |
| -92.2918% | |
| -50.6464% | |
| -28.982% | |
| -27.0902% | |
| -32.4813% | |
| -36.8512% | |
| -24.8073% | |
| -32.0719% | |
| -45.1237% | |
| -58.7833% | |
| -140.3937% | |
| -153.0844% | |
| -141.1717% | |
| -124.5314% | |
| -7.1591% | |
| 33.1298% | |
| 51.4882% | |
| 2.8912% | |
| -4.1964% | |
| -0.9284% | |
| 0.5417% | |
| -4.1892% | |
| 4.4486% | |
| 2.8299% | |
| -8.6941% |